POCT Offers Cost-Effective Convenience and Improved HbA1c Analysis

A glycated hemoglobin (HbA1c) analyzer for near-patient monitoring of diabetes is cost-effective and easy-to-use.

Called the Quo-Test, the compact analyzer will be demonstrated by BHR at Heart UK’s annual conference in Bristol (UK), during July 2013.

A product of EKF Diagnostics (Cardiff, United Kingdom), Quo-Test provides rapid measurement of HbA1c at the point-of-care (POC). The analyzer provides lab-accurate results in only four minutes from 4 μL of venous or finger prick blood. This enables clinicians to make immediate decisions for a patient’s diabetes management and should result in improved diabetic control, better patient outcomes and enhanced clinic efficiency, with fewer patient visits, and subsequent economic benefits.

CE marked, Quo-Test is fully automated with intuitive step-by-step onscreen instructions minimizing training time. The compact analyzer also ensures efficient data handling, with a barcode reader included and storage of up to 7,000 results, which can be downloaded to a laboratory information system (LIS) via its USB port. The results are unaffected by hemoglobin variants because Quo-Test uses the boronate affinity method, which is interference free.

Andrew Greaves, BHR Sales Director, commented, “Due to the evident link between diabetes and heart disease, EKF Diagnostics’ Quo-Test is an ideal analyzer to showcase at this event [Heart UK] since it delivers easy and reliable measurement of HbA1c used for the detection and management of diabetes at the point-of-care.”

Related Links:
BHR
EKF Diagnostics